GO
Loading...

Bristol-Myers Squibb Co

More

  • Final Glance: Pharmaceuticals companies Wednesday, 16 Apr 2014 | 6:02 PM ET

    Baxter International Inc. rose$. 09 or. 1 percent, to $73.45. Bristol-Myers Squibb Co. rose$. 94 or 2.0 percent, to $49.11. Hospira fell$. 43 or 1.0 percent, to $43.00.

  • Midday Glance: Pharmaceuticals companies Wednesday, 16 Apr 2014 | 1:30 PM ET

    Baxter International Inc. fell$. 04 or. 1 percent, to $73.32. Bristol-Myers Squibb Co. rose $1.00 or 2.1 percent, to $49.17. Hospira fell$. 52 or 1.2 percent, to $42.91.

  • Early Glance: Pharmaceuticals companies Wednesday, 16 Apr 2014 | 10:27 AM ET

    Baxter International Inc. rose$. 51 or. 7 percent, to $73.87. Bristol-Myers Squibb Co. rose$. 40 or. 8 percent, to $48.57. Hospira fell$. 24 or. 6 percent, to $43.19.

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • Final Glance: Pharmaceuticals companies Monday, 14 Apr 2014 | 6:01 PM ET

    Baxter International Inc. rose$. 78 or 1.1 percent, to $72.76. Bristol-Myers Squibb Co. fell$. 87 or 1.8 percent, to $47.96. Hospira rose$. 79 or 1.9 percent, to $42.93.

  • Midday Glance: Pharmaceuticals companies Monday, 14 Apr 2014 | 2:08 PM ET

    Baxter International Inc. rose$. 79 or 1.1 percent, to $72.77. Bristol-Myers Squibb Co. fell$. 39 or. 8 percent, to $48.44. Hospira rose $1.35 or 3.2 percent, to $43.49.

  • Early Glance: Pharmaceuticals companies Monday, 14 Apr 2014 | 10:21 AM ET

    Baxter International Inc. rose$. 47 or. 7 percent, to $72.45. Bristol-Myers Squibb Co. fell$. 07 or. 1 percent, to $48.77. Hospira rose$. 10 or. 2 percent, to $42.24.

  • Final Glance: Pharmaceuticals companies Friday, 11 Apr 2014 | 6:03 PM ET

    Baxter International Inc. fell$. 28 or. 4 percent, to $71.98. Bristol-Myers Squibb Co. fell$. 46 or. 9 percent, to $48.83. Hospira fell$. 58 or 1.4 percent, to $42.14.

  • Midday Glance: Pharmaceuticals companies Friday, 11 Apr 2014 | 1:51 PM ET

    Baxter International Inc. rose$. 15 or. 2 percent, to $72.41. Bristol-Myers Squibb Co. rose$. 07 or. 1 percent, to $49.36. Hospira fell$. 26 or. 6 percent, to $42.46.

  • LOS ANGELES/ LONDON April 11- Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.

  • WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

  • Early Glance: Pharmaceuticals companies Thursday, 10 Apr 2014 | 10:24 AM ET

    Baxter International Inc. fell$. 37 or. 5 percent, to $73.08. Bristol-Myers Squibb Co. fell$. 45 or. 9 percent, to $50.12. Hospira fell$. 56 or 1.3 percent, to $43.65.

  • April 10- A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.

  • April 10- A two-drug combination being tested by Merck& Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.

  • Final Glance: Pharmaceuticals companies Wednesday, 9 Apr 2014 | 6:06 PM ET

    Baxter International Inc. rose $1.15 or 1.6 percent, to $73.45. Bristol-Myers Squibb Co. rose $1.51 or 3.1 percent, to $50.57. Hospira rose$. 69 or 1.6 percent, to $44.21.

  • Midday Glance: Pharmaceuticals companies Wednesday, 9 Apr 2014 | 1:15 PM ET

    Baxter International Inc. rose$. 62 or. 9 percent, to $72.92. Bristol-Myers Squibb Co. rose$. 87 or 1.8 percent, to $49.93. Hospira rose$. 52 or 1.2 percent, to $44.04.

  • LONDON, April 9- The World Health Organisation wants a "concerted effort" to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide.

  • Early Glance: Pharmaceuticals companies Tuesday, 8 Apr 2014 | 10:43 AM ET

    Baxter International Inc. rose$. 24 or. 3 percent, to $72.73. Johnson& Johnson rose$. 04 or percent, to $97.93. Eli Lilly& Co. rose$. 04 or. 1 percent, to $58.66.

  • April 4- Amgen Inc said its experimental drug to treat a deadly form of skin cancer did not significantly improve overall survival rates in patients enrolled in a late-stage study.

  • LONDON, April 2- GlaxoSmithKline Plc has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit.

Most Popular Video

Monday, 21 Apr 2014 | 12:02 AM ET

Simon Grose-hodge, Head of Investment Advisory, South Asia at LGT Bank Singapore, remains overweight on developed markets as the U.S. and Europe are showing signs of recovery.

Sunday, 20 Apr 2014 | 9:42 PM ET

Caroline Russell, CEO of Boh Plantations, speaks to CNBC's Julia Wood about the company's focus on maintaining dominance in its home market of Malaysia.

Sunday, 20 Apr 2014 | 8:47 PM ET

As the Beijing Auto Show kicks off on Monday, Martin Winterkorn, Chairman and CEO at Volkswagen, says plug-in hybrids will dominate its lineup in China for alternative energy cars.